Skip to main content
Fig. 2 | BMC Pulmonary Medicine

Fig. 2

From: Serum heme oxygenase-1 measurement is useful for evaluating disease activity and outcomes in patients with acute respiratory distress syndrome and acute exacerbation of interstitial lung disease

Fig. 2

Variation in serum HO-1 levels at the time of diagnosis (D0) and 7 (D7) and 14 (D14) days from the diagnosis. Serum HO-1 levels were measured at the time of ARDS or AE-ILD diagnosis (D0) and 7 (D7) and 14 (D14) days from the diagnosis. Serum HO-1 levels at D0, D7, and D14 were available in 35 of 55 patients (64%). Of the 35 patients, 18 (51%) had ARDS and 17 (49%) had AE-ILDs. As shown in a (all patients), serum HO-1 at D0, D7, and D14 tended to decrease, and serum HO-1 levels at D14 were significantly decreased compared with those at D0 (81.1 ± 9.3 ng/mL vs. 60.9 ± 52.4 ng/mL, respectively, P = 0.016). Furthermore, as shown in b, significant differences were observed between serum HO-1 levels at D0 and D14 in the ARDS group (95.7 ± 61.6 ng/mL vs. 67.8 ± 61.3 ng/mL, respectively, P = 0.041). As shown in c, while serum HO-1 levels of the AE-ILD group tended to decrease, these differences were not significant. As shown in d, 28 (51%) were treated with corticosteroid and had available HO-1 levels at the time of D0 and D7 and D14 and no significant difference was observed between serum HO-1 levels at D0, D7, and D14 (77.1 ± 56.3 ng/mL vs. 78.4 ± 66.0 ng/mL vs. 64.7 ± 57.8 ng/mL, respectively)

Back to article page